, CI = confidence interval

, GnRH = gonadotrophin-releasing hormone

. Iqr-=-interquartile-range, C. Alviggi, G. E. Cognigni, G. Morgante, B. Cometti et al., A prospective, randomised, investigator-blind, controlled, clinical study on the clinical efficacy and tolerability of two highly purified hMG preparations administered subcutaneously in women undergoing IVF, Gynecol. Endocrinol, vol.29, pp.695-699, 2013.

F. J. Broekmans, J. Kwee, D. J. Hendriks, B. W. Mol, and C. B. Lambalk, A systematic review of tests predicting ovarian reserve and IVF outcome, Hum. Reprod. Update, vol.12, pp.685-718, 2006.

A. French-biomedicine, Le rapport médical et scientifique de l'assistance médicale à la procréation et de la génétique humaines en France. Activité d'Assistance Médicale à la Procréation, 2016.

E. Hershkop, L. Segal, O. Fainaru, and S. Kol, Model' versus 'everyday' patients: can randomized controlled trial data really be applied to the clinic?, Reprod. Biomed, vol.34, pp.274-279, 2017.

R. Leão, B. F. De, and S. C. Esteves, Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech, Clinics (Sao Paulo), vol.69, pp.279-293, 2014.

G. Lockwood, B. Cometti, J. Bogstad, K. Erb, C. De-geyter et al., A randomized controlled trial comparing the efficacy and safety of two HMG preparations gaining their LH bioactivity from different HCG sources, Reprod. Biomed. Online, vol.35, pp.17-27, 2017.

B. W. Mol, P. M. Bossuyt, S. K. Sunkara, G. Velasco, J. A. Venetis et al., Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients, Fertil. Steril, vol.109, pp.968-979, 2018.

E. Munoz, E. Bosch, I. Fernandez, S. Portela, G. Ortiz et al., The role of LH in ovarian stimulation, Curr Pharm Biotechnol, vol.13, pp.409-416, 2012.

C. Niederberger, A. Pellicer, J. Cohen, D. K. Gardner, G. D. Palermo et al., Forty years of IVF, Fertil. Steril, vol.110, pp.185-324, 2018.

N. P. Polyzos and P. Drakopoulos, Management Strategies for POSEIDON's Group 1, Front Endocrinol (Lausanne), vol.10, p.679, 2019.

S. Schneeweiss, Real-World Evidence of Treatment Effects: The Useful and the Misleading, Clin. Pharmacol. Ther, vol.106, pp.43-44, 2019.